How are TaiMed, Theratechnologies, and Trogarzo connected?
TaiMed identifies Theratechnologies as its exclusive U.S. commercialization partner for Trogarzo (ibalizumab-uiyk). [1]
TaiMed’s 2025 statement says their longstanding agreement for marketing and distributing Trogarzo in the United States and Canada remains in effect despite the announced Future Pak transaction. [1]
Dated evidence
| Claim | Value | As of | Source and original quotation |
|---|---|---|---|
| Product and US partner | Trogarzo (ibalizumab-uiyk); Theratechnologies is TaiMed’s exclusive U.S. commercialization partner | 2026-10-22 | Primary sourceexclusive commercialization partner |
| Distribution relationship | TaiMed–Theratechnologies agreement covers marketing and distribution in the U.S. and Canada | 2026-10-22 | Primary sourcein the U.S. and Canada remains in effect |
Not disclosed in the public documents
The checked public partnership-continuity statement does not disclose the full contract, current transfer-price formula or product-level profit split. Document reviewed 2026-10-22
TaiMed Biologics